Tag: Event-Free Survival

Home / Event-Free Survival

Categories

Neoadjuvant/adjuvant nivolumab is approved by the USFDA for resectable non-small cell lung cancer

 On October 3, 2024, the Food and Drug Administration sanctioned nivolumab (Opdivo, Bristol Myers Squibb Company) in conjunction with platinum-doublet chemotherapy as neoadjuvant therapy, succeeded b...
event-free-survival

Scan the code